Jennison Associates LLC decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,864,010 shares of the biopharmaceutical company’s stock after selling 760,927 shares during the quarter. Jennison Associates LLC owned approximately 3.41% of Amicus Therapeutics worth $98,143,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of FOLD. Dimensional Fund Advisors LP lifted its position in shares of Amicus Therapeutics by 374.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,098,083 shares of the biopharmaceutical company’s stock worth $10,518,000 after purchasing an additional 866,793 shares in the last quarter. Norges Bank bought a new stake in shares of Amicus Therapeutics in the fourth quarter worth $14,147,000. Geode Capital Management LLC lifted its position in shares of Amicus Therapeutics by 9.0% in the fourth quarter. Geode Capital Management LLC now owns 2,183,679 shares of the biopharmaceutical company’s stock worth $20,919,000 after purchasing an additional 180,938 shares in the last quarter. Strs Ohio lifted its position in shares of Amicus Therapeutics by 176.9% in the first quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock worth $146,000 after purchasing an additional 6,900 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Amicus Therapeutics by 223.9% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 95,115 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 65,750 shares in the last quarter. 95.01% of the stock is currently owned by institutional investors.
In other Amicus Therapeutics news, Director Michael Raab sold 5,000 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $11.16, for a total value of $55,800.00. Following the transaction, the director now directly owns 13,895 shares in the company, valued at $155,068.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the transaction, the chief executive officer now owns 770,399 shares in the company, valued at $8,589,948.85. The disclosure for this sale can be found here. Over the last quarter, insiders sold 65,000 shares of company stock worth $779,000. Corporate insiders own 2.50% of the company’s stock.
NASDAQ FOLD traded down $0.23 on Friday, hitting $9.84. 2,029,493 shares of the stock were exchanged, compared to its average volume of 3,663,208. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.97 and a current ratio of 7.09. The business’s fifty day moving average is $11.74 and its 200 day moving average is $12.43. Amicus Therapeutics, Inc. has a 52 week low of $8.27 and a 52 week high of $14.61.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The firm had revenue of $44.13 million for the quarter, compared to analyst estimates of $41.14 million. During the same period in the prior year, the firm posted ($0.33) earnings per share. The company’s quarterly revenue was up 107.1% compared to the same quarter last year. As a group, research analysts anticipate that Amicus Therapeutics, Inc. will post -1.31 EPS for the current year.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Article: When can a hold rating present a buying opportunity?
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.